Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Acetone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL304990 | 1.00 | — | — | |
| Acetone SCHEMBL27552921 | 1.00 | LMNA (0.55) | — | |
| Acetone SCHEMBL28012937 | 0.96 | LMNA (0.50) | — | |
| Acetone SCHEMBL28074260 | 0.96 | — | — | |
| Acetone SCHEMBL5610508 | 0.96 | — | — | |
| Acetone SCHEMBL28247209 | 0.96 | — | — | |
| Acetic Acid SCHEMBL27912576 | 0.92 | FFAR3 (0.54) | — | |
| Acetone SCHEMBL9174987 | 0.89 | LMNA (0.43) | — | |
| Acetic Acid SCHEMBL4986972 | 0.87 | FFAR3 (0.58) | — | |
| Acetic Acid SCHEMBL4014382 | 0.87 | FFAR3 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | RENEO PHARMACEUTICALS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240002356-A1 | CRYSTALLINE PPAR-DELTA AGONIST | JOHNSON MATTHEY PLC (GB) | 2024-01-04 | — | — | US | disclosed |
| CN-116814729-A | Method for inducing algae to efficiently synthesize astaxanthin | 海南春蕾海洋生物科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11713301-B2 | Crystalline PPARδ agonist | RENEO PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230233570-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-4185572-A1 | CRYSTALLINE PPAR-DELTA AGONIST | Reneo Pharmaceuticals, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230139502-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220135532-A1 | CRYSTALLINE PPAR-DELTA AGONIST | JOHNSON MATTHEY PLC (GB) | 2022-05-05 | — | — | US | disclosed |
| CN-114380725-A | Method for continuously synthesizing thiophanate methyl | 湖南海利化工股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-4755511-A | Tricyclic pyridazinone compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-07-05 | — | — | US | disclosed |
| EP-0095295-B1 | CYCLIC PEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-01-14 | — | — | EP | disclosed |
| US-RE32311-E | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1986-12-16 | — | — | US | disclosed |
| US-RE32310-E | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1986-12-16 | — | — | US | disclosed |
| EP-0181145-A2 | Heterocyclic compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-05-14 | — | — | EP | disclosed |
| US-4524135-A | DEACYLATION | ELI LILLY AND COMPANY (US) | 1985-06-18 | — | — | US | disclosed |
| US-4482487-A | A-21978C cyclic peptides | ELI LILLY AND COMPANY (US) | 1984-11-13 | — | — | US | disclosed |
| EP-0095295-A1 | Cyclic peptide derivatives | ELI LILLY AND COMPANY (US) | 1983-11-30 | — | — | EP | disclosed |
| US-4399067-A | Derivatives of A-21978C cyclic peptides | ELI LILLY AND COMPANY (US) | 1983-08-16 | — | — | US | disclosed |
| US-4396543-A | Derivatives of A-21978C cyclic peptides | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |